SCHEMBL30837844

SCHEMBL30837844

COc1ccc(CC2OC=CO2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
NNMT P40261 1/20 0.37
CYP11B1 P15538 1/20 0.36
TRPV6 Q9H1D0 1/20 0.36
DAO P14920 1/20 0.36
NAAA Q02083 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36
TUBA3E Q6PEY2 1/20 0.36
TUBA1A Q71U36 1/20 0.36
TUBA1C Q9BQE3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454093 0.76 KDM1A (0.46) KDM1AMAOAMAOBNNMTTRPV6
SCHEMBL91410 0.72 KDM1A (0.44) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL3229511 0.72 NNMT (0.44) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL129502 0.71 KDM1A (0.43) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL20458821 0.71 IDO1 (0.48) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL2642344 0.71 KDM1A (0.43) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL1146238 0.71 LOXL2 (0.53) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL21909727 0.71 KDM1A (0.43) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL5547238 0.71 LOXL2 (0.53) KDM1AMAOAMAOBNNMTCYP11B1
SCHEMBL128892 0.71 MEN1 (0.44) KDM1AMAOAMAOBNNMTCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed